PI3K/AKT/mTOR通路
自噬
西罗莫司
癌症
癌症研究
蛋白激酶B
RPTOR公司
mTOR抑制剂的发现与发展
医学
信号转导
生物信息学
药理学
生物
细胞凋亡
细胞生物学
内科学
遗传学
作者
Eunüs S. Ali,Kangkana Mitra,Shamima Akter,Sarker Ramproshad,Banani Mondal,Ishaq N. Khan,Muhammad Torequl Islam,Javad Sharifi‐Rad,Daniela Călina,William C. Cho
标识
DOI:10.1186/s12935-022-02706-8
摘要
Abstract The PI3K-Akt-mechanistic (formerly mammalian) target of the rapamycin (mTOR) signaling pathway is important in a variety of biological activities, including cellular proliferation, survival, metabolism, autophagy, and immunity. Abnormal PI3K-Akt-mTOR signalling activation can promote transformation by creating a cellular environment conducive to it. Deregulation of such a system in terms of genetic mutations and amplification has been related to several human cancers. Consequently, mTOR has been recognized as a key target for the treatment of cancer, especially for treating cancers with elevated mTOR signaling due to genetic or metabolic disorders. In vitro and in vivo, rapamycin which is an immunosuppressant agent actively suppresses the activity of mTOR and reduces cancer cell growth. As a result, various sirolimus-derived compounds have now been established as therapies for cancer, and now these medications are being investigated in clinical studies. In this updated review, we discuss the usage of sirolimus-derived compounds and other drugs in several preclinical or clinical studies as well as explain some of the challenges involved in targeting mTOR for treating various human cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI